Vacuolar Proton Pump Activators encompass a variety of chemical compounds that, while initially acting as inhibitors, can indirectly lead to the enhancement of the Vacuolar Proton Pump (V-ATPase) functional activity. Bafilomycin A1 and Concanamycin A are specific V-ATPase inhibitors that, at sublethal concentrations, may stimulate a compensatory cellular upregulation of V-ATPase to preserve essential proton gradients across organelle membranes. Similarly, Benzolactone Derivatives and Folimycin, by transiently disrupting V-ATPase-dependent acidification, could trigger adaptive increases in V-ATPase activity to maintain acidic conditions within lysosomes and other organelles. Indolyl Pentadienyl Anions and Archazolid, despite their inhibitory actions on V-ATPase, can lead to a secondary enhancement of the pump's functional activity as the cell attempts to counterbalance disruptions in pH homeostasis. Spirodindolones and Salicylihalamide A, by inhibiting V-ATPase, may inadvertently promote the activation of V-ATPase as part of the cell's intrinsic response to sustain organelle acidification.
Continuing with the theme of indirect activation, Lobatamide C and Oxalyl Phenylalanine Derivatives may potentiate V-ATPase activity by invoking cellular mechanisms designed to overcome the initial inhibition of acidification in compartments like lysosomes and endosomes. Padimate O, distinct from the aforementioned inhibitors, augments cellular ATP levels, which could in turn bolster the energy-dependent activity of V-ATPase, ensuring efficient proton pumping against steep concentration gradients. Lastly, Niclosamide, by uncoupling mitochondrial oxidative phosphorylation, could lead to a compensatory cellular response that indirectly increases V-ATPase activity to preserve intracellular ATP levels. Collectively, these activators, through their complex interaction with cellular homeostatic mechanisms, facilitate the indirect enhancement of V-ATPase activity, crucial for maintaining the acid-base balance within various cellular organelles.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Bafilomycin A1 acts as a specific inhibitor of V-ATPase. When used at low concentrations, it can transiently enhance proton pump activity by inducing compensatory cellular mechanisms to maintain proton gradients. | ||||||
Concanamycin A | 80890-47-7 | sc-202111 sc-202111A sc-202111B sc-202111C | 50 µg 200 µg 1 mg 5 mg | $66.00 $167.00 $673.00 $2601.00 | 109 | |
Concanamycin A is a V-ATPase inhibitor. Like bafilomycin, at low doses, it could potentially cause cells to upregulate V-ATPase activity as a compensatory response. | ||||||
Niclosamide | 50-65-7 | sc-250564 sc-250564A sc-250564B sc-250564C sc-250564D sc-250564E | 100 mg 1 g 10 g 100 g 1 kg 5 kg | $38.00 $79.00 $188.00 $520.00 $1248.00 $5930.00 | 8 | |
Niclosamide uncouples mitochondrial oxidative phosphorylation, which may lead to an indirect increase in V-ATPase activity as cells work to maintain ATP levels. | ||||||